These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25488087)

  • 41. Ovarian cancer screening.
    van Nagell JR; Pavlik EJ
    Clin Obstet Gynecol; 2012 Mar; 55(1):43-51. PubMed ID: 22343228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
    Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
    Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The UKCTOCS experience--reasons for hope?
    Menon U; Kalsi J; Jacobs I
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S18-20. PubMed ID: 22543913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ovarian cancer screening.
    Alexander-Sefre F; Menon U; Jacobs IJ
    Hosp Med; 2002 Apr; 63(4):210-3. PubMed ID: 11995270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions.
    Macuks R; Baidekalna I; Donina S
    Tumour Biol; 2012 Oct; 33(5):1811-7. PubMed ID: 22696162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors.
    Moszynski R; Szpurek D; Michalak S; Szubert S; Sajdak S
    Eur J Gynaecol Oncol; 2009; 30(5):552-6. PubMed ID: 19899414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening postmenopausal women for ovarian cancer: a systematic review.
    Fung MF; Bryson P; Johnston M; Chambers A;
    J Obstet Gynaecol Can; 2004 Aug; 26(8):717-28. PubMed ID: 15307976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of two ovarian malignancy prediction models based on age sonographic findings and serum CA125 measurement.
    Arab M; Yaseri M; Ashrafganjoi T; Maktabi M; Noghabaee G; Sheibani K
    Asian Pac J Cancer Prev; 2012; 13(8):4199-202. PubMed ID: 23098430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
    Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
    Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
    Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
    Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening the postmenopausal ovary.
    Nachtigall LE
    Menopause; 2009; 16(6):1092. PubMed ID: 19779315
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
    Morgante G; la Marca A; Ditto A; De Leo V
    Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Designing early detection programs for ovarian cancer.
    Hartge P
    J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.